Tag:
Zyprexa
Latest Headlines
Latest Headlines
Mined doctor-patient data gives drugmakers insight for targeted marketing
The recent layoffs of hundreds of drug sales reps mean there are fewer people in the field calling on doctors to see what they are prescribing. But they don't have to--drugmakers have found new tools that actually can tell them more about doctors' prescribing patterns than the physicians even know themselves.
UPDATED: Lilly tells 1,624 their sales jobs are gone or changed
Salesforce cuts are coming down at Eli Lilly, and 40% of its U.S. sales force will be out. According to the company, the drugmaker sent a state Warn Notice to 1,624 sales positions, of which about 1,000 will be let go.
Lilly cost-cutting and price hikes pay off with Q1 earnings beat
The moral of Eli Lilly's first-quarter performance is this: Raise prices and cut costs.
Dr. Reddy's feels hangover after hot Zyprexa launch
India's Dr. Reddy's Laboratories hit the U.S. market last year with a copycat version of Eli Lilly's ($LLY) Zyprexa and 6 months of exclusivity. But now, it is feeling the hangover and had to report a miserable quarter by comparison.
Lilly betting B12 can protect blockbuster Alimta from generics
Most people take vitamins to boost their energy or protect against colds. But Eli Lilly ($LLY) is hoping vitamin B12 will protect it from losing up to $3.5 billion in sales a year.
U.S. branded sales to end 2012 with 3.5% decline
By the time the ball drops in Times Square this year, branded drug sales will have dropped 3.5%. So says a new report on U.S. spending, which pegs this year's decline at that rate--and forecasts an annual decline of 2.6%, on average, over the next several years.
Sales, profits fall short for Lilly's 'ho-hum' quarter
It could have been worse. That's the general reaction to Eli Lilly's ($LLY) third-quarter results. The company fell short of analyst estimates, both on earnings and on sales. Generics lopped off 68% of Zyprexa's sales. Other key drugs didn't perform as expected, either.
Fitch flags big obstacles ahead for Eli Lilly
The credit-analysis firm confirmed the drugmaker's current ratings, but changed its outlook to "negative" from "stable." That's because Lilly is walking toward two big patent expirations, fresh off its recent loss of Zyprexa exclusivity.
Report: Schizophrenia drug sales are shrinking, but growth will return
The market for schizophrenia drugs will shrink over the next couple of years, Decision Resources finds, but will bounce back after that, thanks to new drugs that can be priced at a premium to older treatments.
AZ's Nexium tops Q2 sales ranks, with BMS' Abilify on its heels
Now that Plavix and Lipitor are down for the count, AstraZeneca's Nexium is the reigning heavyweight drug champion. According to Drugs.com, the stomach drug outsold all other branded drugs during the second quarter, with $1.38 billion in revenues. But Nexium's dominance could be short-lived.
